| The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor‘s conference coverage. |
Vemurafenib improves outcomes among patients with non–small cell lung cancer (NSCLC) with a BRAFV600 mutation, according to the results of a basket study presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.1
One to 4 percent of patients with NSCLC harbor a BRAFV600 mutation. For the NSCLC cohort of the phase 2 VE-BASKET study (ClinicalTrials.gov Identifier: NCT01524978), researchers evaluated data from 62 patients with NSCLC treated with vemurafenib.
Continue Reading
Half of the patients received at least 2 prior therapies.
Of the 8 previously untreated patients, 3 had a confirmed response and 5 had stable disease. Of the 54 previously treated patients, 20 had a confirmed response and 21 had stable disease.
The overall median progression-free survival (PFS) and overall survival (OS) rates were 6.5 and 15.4 months, respectively.
The most common adverse event was nausea; 6 patients discontinued treatment due to serious adverse events, which included keratoacanthoma and squamous cell carcinoma of the skin.
The authors concluded that “vemurafenib showed evidence of encouraging efficacy in [patients] with NSCLC with BRAFV600 mutation, with prolonged PFS in previously untreated [patients]; median OS was not estimable due to ongoing responses. The safety profile of vemurafenib was similar to that seen in melanoma studies.”
RELATED: Midtreatment FDG-PET-Driven RT Escalation Promising in NSCLC
Read more of Cancer Therapy Advisor‘s coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.
Reference
- Subbiah V, Gervais R, Riely GJ, et al. Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation. J Clin Oncol. 2017;34(suppl; abstr 9074).
